Should I buy or sell Orchard Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ORTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORTX, but not buy additional shares or sell existing shares. View ORTX analyst ratings or view top-rated stocks .

What is Orchard Therapeutics' stock price target for 2024?

3 analysts have issued twelve-month price targets for Orchard Therapeutics' shares. Their ORTX share price targets range from $16.00 to $34.00. On average, they anticipate the company's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 49.7% from the stock's current price. View analysts price targets for ORTX or view top-rated stocks among Wall Street analysts .

How were Orchard Therapeutics' earnings last quarter?

Orchard Therapeutics plc (NASDAQ:ORTX) posted its quarterly earnings results on Monday, May, 15th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($1.61) by $1.49. The firm earned $1.24 million during the quarter, compared to analyst estimates of $6.48 million. Orchard Therapeutics had a negative net margin of 333.90% and a negative trailing twelve-month return on equity of 74.94%.

When did Orchard Therapeutics' stock split?

Orchard Therapeutics shares reverse split before market open on Friday, March 10th 2023. The 1-10 reverse split was announced on Friday, March 10th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Orchard Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE) , SCYNEXIS (SCYX) , Matinas BioPharma (MTNB) , Viking Therapeutics (VKTX) , Allena Pharmaceuticals (ALNA) , Corbus Pharmaceuticals (CRBP) , Entasis Therapeutics (ETTX) , Selecta Biosciences (SELB) and VBI Vaccines (VBIV) .

When did Orchard Therapeutics IPO?

Orchard Therapeutics (ORTX) raised $200 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 13,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

NASDAQ:ORTX

Orchard Therapeutics (ORTX) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free ORTX Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $16.70
▼
$16.70
50-Day Range: $16.40
▼
$16.70
52-Week Range: $4.24
▼
$16.72

Volume: N/A
Average Volume: 157,287 shs
Market Capitalization: $380.09 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.00

Stock Analysis Analyst Forecasts Earnings Headlines Insider Trades Ownership Short Interest Social Media

Get Orchard Therapeutics alerts:

Orchard Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 49.7% Upside
$25.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.01
Based on 29 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($5.25) to ($4.85) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.54 out of 5 stars

Medical Sector

867th out of 918 stocks

Biotechnology Industry

10th out of 15 stocks

3.2

Analyst's Opinion

Consensus Rating
Orchard Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Orchard Therapeutics has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for ORTX.

0.0

Dividend Strength

Dividend Yield
Orchard Therapeutics does not currently pay a dividend.
Dividend Growth
Orchard Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ORTX.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 29 news articles for Orchard Therapeutics this week, compared to 9 articles on an average week.
Search Interest
1 people have searched for ORTX on MarketBeat in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Orchard Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.91% of the stock of Orchard Therapeutics is held by insiders.
Percentage Held by Institutions
Only 29.90% of the stock of Orchard Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Orchard Therapeutics are expected to grow in the coming year, from ($5.25) to ($4.85) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Orchard Therapeutics is -17.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Orchard Therapeutics is -17.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Orchard Therapeutics has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Orchard Therapeutics Stock (NASDAQ:ORTX)

Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom. As of January 24, 2024, Orchard Therapeutics plc operates as a subsidiary of Kyowa Kirin Co., Ltd..

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

ORTX Stock News Headlines

April 19, 2024 | msn.com

TDOT: I-40 West closed near Crab Orchard after vehicle overturns

April 18, 2024 | msn.com

Meghan Markle continues to lean into quiet luxury looks as American Riviera Orchard drops first product

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 18, 2024 | msn.com

Hijacking Meghan Markle's Orchard: Royal Fan Infiltrates Ex-Actress' Glossy Brand Website to Write Their 'Thoughts Are With Kate'

April 18, 2024 | yahoo.com

Meghan Markle’s A-List pals Mindy Kaling, Tracee Ellis Ross show off American Riviera Orchard jams she gifted to just 50 people

April 18, 2024 | msn.com

Meghan Markle's American Riviera Orchard Might Benefit the Royal Family in This Unexpected Way

April 18, 2024 | msn.com

Construction, and traffic delays, to resume at Port Orchard's Bay Street roundabout

April 18, 2024 | yahoo.com

Yes, That’s Meghan Markle’s Calligraphy on American Riviera Orchard’s Logo

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 17, 2024 | yahoo.com

Man arrested in connection with 2023 Plum Orchard area homicide

April 17, 2024 | msn.com

Meghan Markle’s first American Riviera Orchard product revealed, and fans are not impressed

April 17, 2024 | msn.com

Meghan Markle’s American Riviera Orchard has a personal touch that went unnoticed

April 17, 2024 | msn.com

Meghan Markle urged to 'expand her outreach' if American Riviera Orchard is to succeed

April 16, 2024 | msn.com

Meghan Markle pumps up the jam as she introduces American Riviera Orchard jelly, sends it to influencer pals

April 16, 2024 | msn.com

Meghan Markle's lifestyle brand American Riviera Orchard unleashes first product

April 16, 2024 | msn.com

Duchess Meghan teases first product from American Riviera Orchard lifestyle brand

April 16, 2024 | msn.com

Meghan Markle’s American Riviera Orchard Line: All We Know So Far

April 16, 2024 | msn.com

Meghan Markle's American Riviera Orchard products: Strawberry jam and beyond

April 16, 2024 | msn.com

Meghan Markle's American Riviera Orchard Just Released Its First Product — & It's Quite Exclusive

April 16, 2024 | msn.com

Meghan: Jam the first product released from Duchess of Sussex's new lifestyle brand American Riviera Orchard

April 16, 2024 | mirror.co.uk

Everything we know about American Riviera Orchard as Meghan Markle teases products

April 16, 2024 | yahoo.com

Meghan Markle Reveals First American Riviera Orchard Product

April 16, 2024 | msn.com

Meghan, Duchess of Sussex unveils first product from American Riviera Orchard

April 16, 2024 | mirror.co.uk

Meghan Markle gives sneak peek at products from her new brand American Riviera Orchard

April 16, 2024 | mirror.co.uk

Meghan Markle finally launches first long-awaited product from American Riviera Orchard

April 16, 2024 | msn.com

Meghan Markle unveils first American Riviera Orchard jam, sends it to influencer pals

April 14, 2024 | msn.com

Fermanagh 0-9 Armagh 3-11: 'We looked hungry' - Orchard boss Kieran McGeeney

See More Headlines

Receive ORTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/15/2023
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:ORTX
CUSIP: N/A
CIK: 1748907
Web: www.orchard-tx.com
Phone: 442038088286
Fax: N/A
Employees: 166
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $25.00
High Stock Price Target: $34.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +49.7%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.94)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-150,660,000.00
Net Margins: -333.90%
Pretax Margin: -334.54%
Return on Equity: -74.94%
Return on Assets: -33.51%

Debt

Debt-to-Equity Ratio: 0.20
Current Ratio: 3.12
Quick Ratio: 2.98

Sales & Book Value

Annual Sales: $22.66 million
Price / Sales: 16.77
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.74 per share
Price / Book: 2.16

Miscellaneous

Outstanding Shares: 22,760,000
Free Float: 22,099,000
Market Cap: $380.09 million
Optionable: Optionable
Beta: 0.55

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Hubert Baburaj Gaspar M.D. (Age 61)
Ph.D., CEO, Member of Scientific Advisory Board & Executive Director
Comp: $901.42k
Mr. Frank Edward Thomas (Age 55)
President & COO
Comp: $763.95k
Dr. Nicoletta Loggia Ph.D.
R.Ph., Chief Technical Officer
Dr. Fulvio Mavilio Ph.D.
Chief Scientific Officer
Ms. Renee T. Leck
Head of Investor Relations
Benjamin Navon
Director of Corporate Communications
Mr. John Cerio
Chief Human Resource Officer
Mr. Robin Kenselaar
Senior VP & GM of EMEA Commercial Operations
Mr. Braden Parker
Chief Commercial Officer
Dr. Leslie Meltzer Ph.D.
Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ORTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Orchard Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ORTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORTX, but not buy additional shares or sell existing shares.
View ORTX analyst ratings or view top-rated stocks.
What is Orchard Therapeutics' stock price target for 2024?: 3 analysts have issued twelve-month price targets for Orchard Therapeutics' shares. Their ORTX share price targets range from $16.00 to $34.00. On average, they anticipate the company's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 49.7% from the stock's current price.
View analysts price targets for ORTX or view top-rated stocks among Wall Street analysts.
How were Orchard Therapeutics' earnings last quarter?: Orchard Therapeutics plc (NASDAQ:ORTX) posted its quarterly earnings results on Monday, May, 15th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($1.61) by $1.49. The firm earned $1.24 million during the quarter, compared to analyst estimates of $6.48 million. Orchard Therapeutics had a negative net margin of 333.90% and a negative trailing twelve-month return on equity of 74.94%.
When did Orchard Therapeutics' stock split?: Orchard Therapeutics shares reverse split before market open on Friday, March 10th 2023. The 1-10 reverse split was announced on Friday, March 10th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Orchard Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), Selecta Biosciences (SELB) and VBI Vaccines (VBIV).
When did Orchard Therapeutics IPO?: Orchard Therapeutics (ORTX) raised $200 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 13,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

This page (NASDAQ:ORTX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Orchard Therapeutics (ORTX) Stock Price, News & Analysis

Orchard Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Orchard Therapeutics Stock (NASDAQ:ORTX)

ORTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ORTX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™